Storys zum Thema Economy

26.09.2006 – 09:05
Cordis Medizinische Apparate GmbH
Cordis Corporation Launches CYPHER SELECT(TM) Plus Stent
Paris (ots/PRNewswire) - - Shipment of First Third-Generation Drug-eluting Stent Starts Cordis Corporation, the world leader in the drug-eluting stent market, announced today the launch of the CYPHER SELECT(TM) Plus Stent. The first third-generation drug-eluting stent is now available to physicians and patients in many markets around the world, including countries in Western and Eastern Europe, Asia Pacific ...
mehr
26.09.2006 – 08:03
sanofi-aventis Group
Sanofi pasteur Cell Culture-Based Seasonal Influenza Vaccine Enters First Clinical Trial
SWIFTWATER, Pennsylvania & LYON, France, September 26 (ots/PRNewswire) - - Flu Vaccine Based on New Technology Within U.S. Government Preparedness Program Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), initiated its first clinical study today with a new generation of seasonal influenza vaccine produced using cell ...
mehr
19.09.2006 – 14:45
sanofi-aventis Group
Sanofi pasteur Broadens Pandemic Preparedness With First Clinical Trial of Novel Cell Based H7N1 Vaccine
Lyon, France (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has within the framework of FLUPAN, a collaborative research project funded by the European Commission, generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine. This trial will broaden ...
mehr
19.09.2006 – 09:05
World Federation for Mental Health
Young Physicians Call for Better Medical School Training in Depression
Paris (ots/PRNewswire) - - Multi-National Survey Highlights Gaps in PCPs Knowledge About Depression and Painful Physical Symptoms Nine of 10 young primary care physicians (PCPs) believe medical school training about depression -- specifically regarding its painful physical symptoms -- needs to be improved, according to findings from a multi-national survey ...
mehr
18.09.2006 – 21:04
Pfizer AG
Pfizer's Lyrica(R) Approved in Europe for Difficult-to-Treat Nerve Pain
New York (ots/PRNewswire) - - Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis - A robust and unprecedented clinical program involving more than 10,000 patients supports Lyrica's efficacy and safety in ...
mehr
18.09.2006 – 14:19
AstraZeneca GmbH
New Data Offers Hope to Patients With Bipolar Disorder and Schizophrenia
Paris (ots/PRNewswire) - - For Healthcare and Medical Reporters (non-US) Bipolar disorder is the sixth largest cause of disability worldwide in people aged 15-44 years[1] and is commonly mistaken for other diseases such as acute depression. Consequently, people may suffer with symptoms for years before receiving appropriate treatment and up to half of all ...
mehr

16.09.2006 – 13:46
Eli Lilly and Company
New Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Insulin Glargine
Copenhagen, Denmark (ots/PRNewswire) - - Patients Taking Exenatide Lost Weight While Patients Taking Insulin Glargine Gained Weight Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study indicating that exenatide improves blood sugar levels as effectively as insulin glargine (Lantus(R), Sanofi ...
mehr
14.09.2006 – 16:10
Boston Scientific
Safety and Efficacy of Drug-Eluting Stents Reaffirmed in New England Journal of Medicine Articles and Editorial
Natick, Massachusetts (ots/PRNewswire) - Boston Scientific Corporation (NYSE: BSX) today welcomed the results of two studies and an editorial published in today's edition of The New England Journal of Medicine (NEJM), all of which reaffirmed the safety and efficacy of drug-eluting stents. Commenting on the ...
mehr
14.09.2006 – 14:08
The Bill & Melinda Gates Foundation
Gates Foundation Commits Nearly US$70 Million to Help Fight Neglected Tropical Diseases
Seattle (ots/PRNewswire) - - Four Grants Support Development of Vaccines and Better Drugs, and Launch of New Medical Journal The Bill & Melinda Gates Foundation today announced four grants totaling US$68.2 million to help accelerate research on neglected tropical diseases, including hookworm, leishmaniasis, and trypanosomiasis, which kill or disable ...
mehr
14.09.2006 – 11:04
Eli Lilly and Company
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
Copenhagen, Denmark (ots/PRNewswire) - - Patients on exenatide lost weight, while insulin aspart patients gained weight - Eli Lilly and Company (NYSE: LLY) and Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study indicating that exenatide improves blood sugar levels as effectively as biphasic insulin aspart 30/70 (NovoMix 30(R), ...
mehr
14.09.2006 – 11:04
Eli Lilly and Company
Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes
Copenhagen, Denmark (ots/PRNewswire) - Eli Lilly and Company (NYSE: LLY), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), and Alkermes, Inc. (Nasdaq: ALKS) today announced detailed results from a safety and efficacy study of the long-acting release (LAR) formulation of exenatide. Data from the study demonstrated ...
mehr
14.09.2006 – 09:08
Pfizer AG
Exubera Effective in Diabetes Patients who Have Respiratory Infections or are Exposed to Passive Cigarette Smoke, New Analyses Show
Copenhagen, Denmark (ots/PRNewswire) - - Twice as Many People With Uncontrolled Type 2 Diabetes Would Accept Insulin if Offered Exubera, Even in Countries Where Pens are Commonly Used, Additional Study Shows - Patients With Diabetes Gained Less Weight With Exubera Than With Injectable ...
mehr

14.09.2006 – 08:04
Shire Pharmaceuticals Group Plc
New Treatment a Success for Anaemia Associated With Chronic Kidney Disease
Basingstoke, England (ots/PRNewswire) - - Not for Distribution in the United States The first anti-anaemia treatment produced in a human cell line, DYNEPO(R) (epoetin delta), can effectively control anaemia in patients with chronic kidney disease (CKD[x]) according to two Phase III studies presented for the first time today.(1),(2) Patients with kidney ...
mehr
12.09.2006 – 18:19
Pfizer AG
Exubera Hailed as Innovation In Prestigious European and American Awards
New York (ots/PRNewswire) - - WSJ/Professor Pedro Nueno: "The drug could encourage diabetes sufferers to get treatment earlier and more often. This has such a tremendous advantage for a huge number of people worldwide. It is a real breakthrough." - PharmaBarometer: "Despite only being launched into the German market in May 2006, it has been immediately ...
mehr
12.09.2006 – 16:56
Medify Solutions Ltd.
Medify Solutions Limited (Pink Sheets - MFYS) - Forward Order Book
Gateshead, England (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MFYS), today received partner approval to release the current forward order book. These figures include all current and forward sales for both the UK and European operations. Medify Solutions Limited is contracted to deliver the MedifyRemote application to the UK and the Italian ...
mehr
11.09.2006 – 18:25
Procter & Gamble
Seven Straight Years - P&G Ranked Top of Industry Group by Dow Jones Sustainability Index
Newcastle, England (ots/PRNewswire) - The Procter & Gamble Company (P&G) has been selected as the "Personal & Household Goods" Super Sector Industry Leader in the global Dow Jones Sustainability Index (DJSI) listings for the seventh year in a row. The Dow Jones Sustainability Indexes (DJSI), launched in 1999, are the first global indexes tracking the ...
mehr
11.09.2006 – 15:12
Medify Solutions Ltd.
Medify Solutions Limited: Investors Update September 2006
Toronto, Canada (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MFYS) today issued the latest investors update. The update is available to view on the company's website, www.medifysolutions.com under the latest news section. Company website : www.medifysolutions.com This news release contains forward-looking statements that are subject to certain risks and uncertainties that may cause actual results ...
mehr
11.09.2006 – 10:02
AstraZeneca GmbH
New Website Looks at the Science Behind Stroke
Macclesfield, England (ots/PRNewswire) - - www.novelneuroprotection.com Aims to Increase Understanding of Acute Ischemic Stroke and the Potential Role of Neuroprotection - For Medical Media Only A new resource for the international medical community was launched in September 2006 by AstraZeneca, www.novelneuroprotection.com. This educational site aims to help healthcare professionals understand more about ...
mehr

08.09.2006 – 22:37
sanofi-aventis Group
The New England Journal of Medicine Publishes the STEEPLE Study Which Demonstrated Superior Safety Profile of LOVENOX(r) (Enoxaparin Sodium Injection) Vs. Unfractionated Heparin (UFH) in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention
Paris (ots/PRNewswire) - The New England Journal of Medicine publishes the international STEEPLE trial (Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI): An International Randomized Evaluation), which showed that a single intravenous bolus of enoxaparin of 0.5 mg/kg is associated ...
mehr
07.09.2006 – 19:24
Medify Solutions
Medify Solutions Limited Launches MedifyRemote for BlackBerry
Toronto, Canada (ots/PRNewswire) - - Mobile Access to Clinical Data now Available on BlackBerry Devices Medify Solutions Limited (Pink Sheets - MFYS) today announced that its product portfolio will be available on BlackBerry(R) handsets. The MedifyRemote application allows mobile access to patient notes and clinical systems in real time, helping doctors and nurses to provide better, more efficient and more ...
mehr
07.09.2006 – 08:05
Sanofi-aventis; Bristol-Myers Squibb
European Commission Expands Indication for PLAVIX(R) (clopidogrel bisulfate) Offering New Option for Patients With Most Severe Type of Heart Attack
Paris (ots/PRNewswire) - - PLAVIX indication expanded to include patients with any acute coronary syndromes (ACS) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission has granted a new indication for the antiplatelet ...
mehr
06.09.2006 – 09:32
Pfizer AG
Lipitor More Effective Than Simvastatin in Cutting Risk of Additional Heart Attacks in Patients Who Had a Recent Heart Attack, New Data Suggests
New York (ots/PRNewswire) - - Heart Disease Patients who Were at a Very High Risk for Having a Second Heart Attack and Took Lipitor 80mg Had a 46 Percent Reduction in the Risk of Experiencing Additional Heart Attacks Compared With Patients Taking Simvastatin - Investigator: 'These data suggest the benefit ...
mehr
05.09.2006 – 10:05
Roche Pharmaceuticals
Roche Requests Re-Examination of CHMP Opinion on Tarceva in Pancreatic Cancer at the European Medicines Agency
Basel, Switzerland (ots/PRNewswire) - - First Treatment for Years to Have Shown a Significant Survival Benefit for Patients Roche announced today that it has requested a re-examination of the data supporting the filing of their breakthrough cancer medicine, Tarceva, for the treatment of pancreatic cancer ...
mehr
05.09.2006 – 08:17
Hospital Pitie Salpetriere-Institut du coeur
RIVIERA Registry Identifies Modifiable Predictors of Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention
Barcelona, Spain (ots/PRNewswire) - Results of the multinational, prospective, observational RIVIERA registry (Registry on IntraVenous anticoagulation In the Elective and primary Real world of Angioplasty) announced today at the World Congress of Cardiology 2006- joint meeting of the European Society of ...
mehr

05.09.2006 – 00:32
Pfizer AG
New Lipitor Data Published in The Lancet
New York (ots/PRNewswire) - - Lipitor Reduces Risk of Major Cardiovascular Events Such as Heart Attacks in People With Heart Disease and With a Cluster of Other Major Cardiovascular Risk Factors, Often Referred to as Metabolic Syndrome, New Analysis Shows - Heart Disease Patients With Metabolic Syndrome who Took Lipitor 80mg Dose Reduced Their Risk of Major Cardiovascular Events by Nearly 30 ...
mehr
04.09.2006 – 08:17
sanofi-aventis Group
New Clinical Data Show Enoxaparin Significantly Reduces the Risk of Repeat Heart Attacks and Stroke in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Barcelona (ots/PRNewswire) - - Results of the PCI-ExTRACT Sub-Study Results of the PCI-ExTRACT-TIMI 25 study announced today at the World Congress of Cardiology-European Society of Cardiology 2006 in Barcelona, showed that among patients with ST-segment elevation myocardial infarction (STEMI) who ...
mehr
03.09.2006 – 12:03
Servier
New Study Shows Benefits of Coversyl (R) (Perindopril) in Elderly With Chronic Heart Failure
Barcelona, Spain (ots/PRNewswire) - - Coversyl(R) in PEP-CHF Trial, is the First Agent to Demonstrate Clinical Benefits in Elderly Heart Failure Patients With Diastolic Dysfunction The ACE inhibitor Coversyl(R) (perindopril) provides a number of clinical benefits to elderly people with chronic heart failure according to the results of a study presented at ...
mehr
31.08.2006 – 08:01
shaPE Capital AG
euro adhoc: shaPE Capital AG / quarterly or semiannual financial statement / shaPE stays on course
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 31.08.2006 Pfaeffikon SZ, 31 August 2006 --- For the first six months ending 30 June 2006 shaPEs share price gained 3.2% to CHF 224.00 while the Net Asset Value (NAV) per share decreased by 2.7% to CHF 228.21. The reduced NAV per share relates to ...
mehr
21.08.2006 – 15:04
Isotechnika Inc.
Isotechnika Inc. Announces Promising Results From Phase I TAFA93 Trials
Edmonton, Alberta (ots/PRNewswire) - - Isotechnika Inc. announced today promising results from its Phase I TAFA93 trials. TAFA93, a pro-drug of rapamycin, is a novel small molecule mTOR inhibitor, which is a class of drugs currently used in the prevention of organ rejection in transplantation. mTOR inhibitors are typically used in combination with ...
mehr
17.08.2006 – 13:38
The Alliance for Better Bone Health
Osteoporosis Treatment Now Approved in Europe & US for Men
Paris, France (ots/PRNewswire) - - Male Osteoporosis: Neglected and Under Treated PARIS, France, August 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) this week approved Actonel(R) 35mg (risedronate sodium tablets) for 'treatment to increase bone mass in men with osteoporosis'. This follows the positive outcome in July 2006 of the European application for the additional indication of ...
mehr

Vorherige66676869707172737475Nächste